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An Integrated Chemical proteomics 
Approach for Quantitative Profiling 
of Intracellular ADp-Ribosylation
Karunakaran Kalesh1,2, Saulius Lukauskas1,3, Aaron J. Borg4, Ambrosius P. snijders  4, 
Vinay Ayyappan5, Anthony K. L. Leung  5, Dorian O. Haskard6 & Peter A. DiMaggio  1
ADP-ribosylation is integral to a diverse range of cellular processes such as DNA repair, chromatin 
regulation and RNA processing. However, proteome-wide investigation of its cellular functions has 
been limited due to numerous technical challenges including the complexity of the poly(ADp-ribose) 
(PAR) chains, low abundance of the modification and lack of sensitive enrichment methods. We herein 
show that an adenosine analogue with a terminal alkyne functionality at position 2 of the adenine 
(2-alkyne adenosine or 2YnAd) is suitable for selective enrichment, fluorescence detection and mass 
spectrometry proteomics analysis of the candidate ADP-ribosylome in mammalian cells. Although 
similar labelling profiles were observed via fluorescence imaging for 2YnAd and 6YnAd, a previously 
reported clickable NAD+ precursor, quantitative mass spectrometry analysis of the two probes in 
MDA-MB-231 breast cancer cells revealed a significant increase in protein coverage of the 2YnAd probe. 
To facilitate global enrichment of ADP-ribosylated proteins, we developed a dual metabolic labelling 
approach that involves simultaneous treatment of live cells with both 2YnAd and 6YnAd. By combining 
this dual metabolic labelling strategy with highly sensitive tandem mass tag (TMT) isobaric mass 
spectrometry and hierarchical Bayesian analysis, we have quantified the responses of thousands of 
endogenous proteins to clinical PARP inhibitors Olaparib and Rucaparib.
Protein ADP-ribosylation is a post-translational modification (PTM) where members of a family of enzymes 
known as ADP-ribosyltransferases (or PARPs) covalently link ADP-ribose moieties derived from NAD+ to the 
side chains of several possible amino acid residues (glutamate, aspartate, arginine, lysine, cysteine, serine) on tar-
get proteins. This PTM exists either as a monomer (mono-ADP-ribosylation), consisting of a single ADP-ribose 
moiety on the target residue, or as a polymer (poly-ADP-ribosylation) where a branched polymeric chain of 
ADP-ribose units originates from the target residue. Of the 17 PARPs encoded in the human genome, PARPs 1, 
2 and 3 are known to have important roles in DNA regulation, particularly in the base excision repair pathway1. 
Consequently, PARP inhibitors have been developed as cancer therapeutics to exploit the concept of synthetic 
lethality in patients with germline mutations in BRCA1 or BRCA2 genes2. Beyond the established roles of these 
nuclear PARPs in DNA damage responses, the broad cellular functions of the majority of the other members of 
the PARP family remain elusive primarily due to the lack of analytical techniques for the large-scale profiling of 
intracellular ADP-ribosylation.
Mass spectrometry (MS) proteomics studies of ADP-ribosylation in particular have been limited due to 
numerous technical challenges. These include low specificity and/or affinity when using recombinant macro 
domains3,4, cis-diol binding boronate beads5, antibodies6 or adapted phosphoproteome enrichment strategies7 to 
enrich for this low abundance PTM against complex cellular backgrounds. Additionally, most methods reported 
to date require a priori knockdown of poly-ADP-ribose glycohydrolase (PARG) activity to sufficiently increase 
the baseline level of poly-ADP-ribosylation for MS detection, which is not ideal since PARG knockdown is known 
to induce physiological changes in cells8. A further limitation of many previous studies is that they have been 
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performed under stress induction, which activates PARP1 and thus potentially masks the underlying activities of 
the other PARP enzymes3–7.
Recently, it has been demonstrated that 6-alkyne adenosine (6YnAd), a compound that was previously 
demonstrated to be suitable for labelling poly(A) tails of mRNAs in mammalian cells9, enables sensitive fluo-
rescence profiling of ADP-ribosylated proteins in live cells10. In this work, we analysed the labelling efficiency of 
6YnAd for the first time using tandem mass tag (TMT)-based quantitative proteomics in mammalian cells and 
found that 6YnAd alone limits substrate coverage, but that inclusion of a similar adenosine analogue, 2-alkyne 
adenosine (2YnAd), allows a more comprehensive assessment of the putative ADP-ribosylome. We also report an 
integrated chemical proteomics approach that involves simultaneous treatment of live cells with both 2YnAd and 
6YnAd followed by robust enrichment of the labelled proteome and its sensitive profiling by TMT quantitative 
mass spectrometry.
Results
2-alkyne adenosine (2YnAd) treatment results in labelling of ADP-ribosylated proteins. We 
treated MDA-MB-231 breast cancer cells with equal concentrations of 2YnAd and 6YnAd in parallel. The cells 
were then lysed and the whole-cell proteome was clicked with a trifunctional capture reagent Azido-TAMRA-
Biotin (Suppl. Fig. 1) and resolved on SDS-PAGE. In-gel fluorescence scan revealed qualitatively similar protein 
labelling profiles for both 2YnAd and 6YnAd treatments (Fig. 1A,B). Similarly, following affinity capture of the 
labelled proteins on NeutrAvidin-Agarose resin, the combination of in-gel fluorescence imaging (Fig. 1C) and 
Western blot analysis using an anti-pan-ADP-ribose antibody (Fig. 1D)11 confirmed significant enrichment of 
ADP-ribosylated proteins in both 2YnAd and 6YnAd treated cells relative to the input control lanes.
2YnAd provides greater coverage of ADP-ribosylated targets than 6YnAd. After establishing the 
use of the 2YnAd analogue for live cell labelling of ADP-ribosylated proteins, we performed a proteomic com-
parison of the labelling between 2YnAd and 6YnAd using the highly sensitive tandem mass tags (TMT)-based 
isobaric tagging for quantitative mass spectrometry12. Using the MDA-MB-231 breast cancer cell line as a model 
system, we first developed a workflow (Fig. 2) that involves the following sequential steps: (i) parallel metabolic 
incorporation of 2YnAd and 6YnAd, (ii) bioorthogonal tagging of the ADP-ribosylated proteome using a copper 
(I) catalysed azide-alkyne cycloaddition (CuAAC) click reaction, (iii) affinity enrichment of the labelled pro-
teome using the robust biotin-NeutrAvidin pull-down system, (iv) TMT6plex isobaric labelling and (v) liquid 
chromatography tandem mass spectrometry (LC-MS/MS) analysis.
Our chemical proteomics workflow for profiling intracellular ADP-ribosylation events identified over 1600 
protein targets (Supplementary Dataset File 1, in which proteins previously reported in ADPriboDB13 are high-
lighted in bold), representing a significant improvement in proteomic coverage compared to other published 
studies despite requiring less protein input (500 µg total protein input before affinity enrichment per condition). 
Importantly, statistical analysis of the replicate data sets using the hierarchical Bayesian model implemented in 
LIMMA14 revealed that specific subsets of protein targets were preferentially labelled with either 2YnAd or 6YnAd 
treatment (Fig. 3, Suppl. Fig. 2), despite the overall qualitative similarity between the two probes in the labelling 
observed in the in-gel fluorescence scans (Fig. 1A). The 2YnAd was found to be preferentially incorporated, 
labelling more ADP-ribosylated protein targets than the 6YnAd (Fig. 3). Additionally, analysis of the biological 
pathways of these targets (Suppl. Fig. 3, Supplementary Dataset File 2) specifically revealed a 2YnAd enrichment 
for proteins involved in proteasome regulation, including several 26S proteasomal subunits.
Dual metabolic labelling using both 2YnAd and 6YnAd elucidates the quantitative response 
of thousands of ADP-ribosylated proteins to clinical PARP inhibitors. We rationalised that the 
observed quantitative differences in protein targets labelled by 2YnAd and 6YnAd could be exploited for more 
comprehensive profiling of the cellular ADP-ribosylome by simultaneously treating cells with both compounds 
and combining this dual metabolic labelling approach with our quantitative proteomics workflow. Additionally, 
as several PARP inhibitors have recently emerged as promising cancer therapeutics, we decided to evaluate the 
dual metabolic labelling strategy for comprehensively and quantitatively profiling global changes to the cellular 
ADP-ribosylome upon PARP inhibitor treatment (Fig. 4). We treated MDA-MB-231 cells with equimolar con-
centrations of 2YnAd and 6YnAd to investigate differential labelling of protein ADP-ribosylation in the presence 
of five different concentrations (0, 0.2, 1, 5, 25 µM) of the clinical PARP inhibitors Olaparib and Rucaparib15. The 
samples were combined in a TMT10plex experiment and over 2300 statistically significant hits were identified 
following hierarchical Bayesian analysis (Supplementary Dataset File 3), which is the largest experimental can-
didate data set representing the cellular ADP-ribosylome to date (Fig. 5A). Statistical analysis of the data sets 
revealed a correlative response in the levels of ADP-ribosylation with respect to Olaparib and Rucaparib treat-
ment, which indicates a congruent set of PARP substrates (Fig. 5B), highlighting the robustness and reproduci-
bility of this integrated chemical biology approach. Protein targets found to decrease in ADP-ribosylation upon 
treatment of both inhibitors were captured in the lower left quadrant of the scatter plot (Fig. 5B). Interestingly, 
several mRNA splicing factors (highlighted by cyan rectangles) were found among the most responsive pro-
teins. In Fig. 5C, the dose-dependent response in the levels of ADP-ribosylation to both inhibitors is shown for 
two of these mRNA splicing proteins, namely pre-mRNA splicing factor 38B (PRPF38B) and serine/arginine 
repetitive matrix protein 2 (SRRM2). It is shown that PRPF38B is more sensitive to Olaparib treatment, whereas 
SRRM2 exhibits a congruent response to both PARP inhibitors. Pathway analysis of all the protein targets found 
to decrease in ADP-ribosylation upon treatment with the inhibitors also identified a preferential enrichment for 
factors involved in mRNA splicing (Supplementary Dataset File 4, Suppl. Fig. 4).
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Discussion
Functionalised full-length NAD+ analogues have recently emerged as promising tools for fluorescence-based 
visualisation of ADP-ribosylation in cell-lysates11,16–18 and in cells19,20. Due to the lack of cell-permeability of the 
full-length NAD+ analogues, intracellular labelling has been performed by transient permeabilisation of the cell 
membrane using Triton X-100 surfactants. Although permeabilisation of cell membrane using the surfactant is a 
powerful approach for imaging applications, successful adaptation of the method to large-scale mass spectrom-
etry (MS) proteomics studies of ADP-ribosylation has not been demonstrated to date. Nevertheless, a chemical 
genetic discovery method using clickable full-length NAD+ analogues has recently enabled selective enrichment 
and MS profiling of ADP-ribosylated proteins, although the lack of cell permeability of the NAD+ analogues 
has restricted these studies to cell lysates11. In a recent advancement in the field, Howard Hang and co-workers 
reported a chemical biology approach for live cell labelling of ADP-ribosylated proteins using a terminal alkyne 
functionalised and cell-permeable NAD+-precursor compound, 6-alkyne adenosine (6YnAd)10. Although suc-
cessful labelling of a few hundred ADP-ribosylated proteins was demonstrated using 6YnAd, previous studies 
have shown that the corresponding full-length clickable NAD+ cofactor (6-alkyne-NAD) is a weaker substrate of 
Figure 1. (A) Qualitative assessment of 2YnAd and 6YnAd labelling in MDA-MB-231 cells by in-gel 
fluorescence scanning. Lanes 1 and 6: molecular weight marker; lane 2: DMSO control; lanes 3, 4 and 5 
(1 mM, 0.5 mM and 0.25 mM 2YnAd respectively) and lanes 7, 8 and 9 (1 mM, 0.5 mM and 0.25 mM 6YnAd 
respectively). (B) Coomassie blue staining of the same gel. (C) In-gel fluorescence scan following the metabolic 
incorporation, cell lysis, click chemistry and affinity enrichment. Lane 1: DMSO control; Lanes 2, 3 and 4: 
1 mM, 0.5 mM and 0.25 mM respectively of 2YnAd was used for the metabolic labelling; lane 5: empty and lanes 
6, 7 and 8: 1 mM, 0.5 mM and 0.25 mM respectively of 6YnAd was used for the metabolic labelling. (D) Western 
blot of the same gel after electrotransfer of proteins onto a nitrocellulose membrane probed using an anti-pan-
ADP-ribose antibody (MABE1016, EMD Millipore).
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PARP1 than endogenous NAD+ 16. This raised the question as to whether the placement of the alkyne group on 
the NAD+ cofactor analogue affects binding and utilisation by the different endogenous PARP enzymes.
We aimed to further develop the metabolic labelling strategy using clickable NAD+ precursors, as this 
approach has the unique advantage of labelling of the ADP-ribosylome directly in the native cellular environ-
ment. Since 2-alkyne adenosine (2YnAd), the metabolic precursor for the corresponding full-length clickable 
NAD+ analogue 2-alkyne-NAD+, was also reported to efficiently label the poly(A) tails of mRNA transcripts in 
live cells21 similar to 6YnAd and recent studies have demonstrated that PARP enzymes are more tolerant to sub-
stitutions in this position on NAD+ 19,20, we investigated if 2YnAd can also be used for the metabolic labelling of 
ADP-ribosylome. Our results (Fig. 1) showed for the first time that 2YnAd is also useful for the in-cell labelling of 
ADP-ribosylated proteins similar to the 6YnAd probe.
As with most chemical proteomics approaches, we cannot eliminate the possibility that a fraction of the click-
able adenosine analogues might be utilised for other types of protein modifications. Comparison of the fluores-
cence and Western-blot experiments (Fig. 1C,D) reveals similar band patterns, thus confirming the enrichment 
of ADP-ribosylated proteins, although differences in labelling were also observable between the two. However, 
these techniques are fundamentally different and have their own limitations in sensitivity and selectivity, which 
can vary with protein substrate, and neither are ideal for detecting protein-specific changes in complex mixtures. 
Therefore, we decided to apply quantitative mass spectrometry-based proteomics using the highly sensitive TMT 
isobaric tagging to conduct a head-to-head comparison of the labelling of protein targets by the two probes. The 
TMT labelling strategy offers sample multiplexing and importantly the isobaric nature of the tag results in the 
pooling of peptide signal across all experimental conditions, which increases the sensitivity in detecting lower 
abundance ADP-ribosylated proteins relative to any non-specific background. Hierarchical Bayesian analysis of 
Figure 2. Schematic illustrating the experimental workflow for quantitative comparison of metabolic labelling 
between 2YnAd and 6YnAd. MDA-MB-231 cells were metabolically labelled with 3 different concentrations of 
2YnAd and 6YnAd in parallel. After cell lysis and click reaction with a biotin-containing capture reagent, the 
labelled proteins are affinity enriched on NeutrAvidin-Agarose resins. Stringent washing at this stage removes 
unmodified proteins from the beads. After on-bead reduction, alkylation and tryptic digestion, the eluted 
peptides are desalted and each sample is labelled using a unique TMT6plex channel. After quenching the 
TMT reactions, the 6 samples are mixed together, fractionated and subjected to nanoflow LC-MS/MS analysis. 
Quantification of reporter ions from the MS/MS spectra provides relative quantification of labelling efficiencies 
of the two compounds at all three tested concentrations.
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our TMTsixplex datasets using LIMMA revealed that the 2YnAd was preferentially incorporated as it produced 
more ADP-ribosylated proteins than the 6YnAd probe (Fig. 3), which is only hinted at by the relatively insensitive 
Western-blot analysis (Fig. 1D). This suggests the possibility that the endogenous PARP enzymes elicit a differen-
tial structural preference for the two NAD+ cofactor analogues.
Interestingly, biological pathway analysis of the identified targets revealed enrichment of several proteins 
involved in proteasome regulation specifically among the 2YnAd targets, including several 26S proteasomal sub-
units. 26S proteasomal activity has been previously reported to be promoted by ADP-ribosylation22. Similarly, a 
co-operative interaction between the proteasome subunit PSMD14 and BRCA1 has been implicated in cellular 
responses to DNA double strand breaks23, a niche where nuclear PARPs are known to have key functional roles. It 
has also been suggested that the negatively charged PARylation may serve as a recognition site for the E3 ubiquitin 
protein ligases, which facilitates subsequent degradation of the protein in the 26S proteasome24. However, the 
precise biological function of ADP-ribosylation in proteasome regulation remains unknown.
Our dual metabolic labelling approach involving simultaneous treatment of cells with equimolar concentra-
tions of 2YnAd and 6YnAd probes and its combination with the TMT10plex quantitative proteomics resulted in 
the largest candidate experimental dataset of cellular ADP-ribosylome with over 2300 significant proteins. The 
superior sensitivity of our proteomics technology enabled the systematic profiling of the cellular ADP-ribosylome 
in an unbiased manner. As an example application, we utilised this methodology to elucidate the first direct 
and quantitative comparison between the intracellular response in ADP-ribosylation to two clinical PARP 
inhibitors, Olaparib and Rucaparib, which are able to induce synthetic lethality in homologous recombination 
(HR)-deficient cancers due to germline and/or somatic mutations in BRACA1 or BRACA2 genes2. In particular, 
both inhibitors are FDA-approved for the treatment of patients with advanced ovarian cancer and are used in the 
maintenance treatment of recurrent ovarian epithelial, fallopian tube and primary peritoneal cancer. Olaparib is 
also approved for the treatment of BRACA1/2 mutated metastatic breast cancer and it is expected that these PARP 
inhibitors will find further applications in treating other HR-deficient cancers.
In Fig. 5B it is shown that several mRNA splicing factors exhibited the largest response to the PARP inhibitor 
treatments, which is in agreement with recent reports indicating pivotal functional roles of PARylation in mRNA 
splicing and modulation of RNA25–29. This finding is further supported by a recent CRISPR screen that identified 
several high-confidence mRNA splicing factors, including DDX46 and SRSF11 (lower left quadrant in Fig. 5B), 
which resulted in increased sensitivity to the PARP inhibitor Olaparib across several cell lines when mutated30.
Due to the heterogeneity of the target residues and the variations of the possible branched polymer structures for 
ADP-ribosylation, the development of robust mass spectrometry-based methods for comprehensive site localisation of 
this modification at the proteome-scale remains a challenge. Our approach circumvents the inherent bias arising from 
site promiscuity by enriching the target proteins via the modification and then elucidating the quantitative changes at 
the protein level across a variety of experimental conditions via multiplexed TMT labelling mass spectrometry and 
hierarchical Bayesian analysis. We have also developed a complementary methodology where we enrich for the modi-
fication at the peptide-level (unpublished) and then perform MS/MS site localisation after treatment with reagents such 
as hydroxylamine to reduce the size of the modification11. Using this approach, we have confidently identified several 
sites of ADP-ribosylation (a few representative MS/MS annotations are provided in Suppl. Fig. 6) and also eliminated 
the possibility of other modifications that could originate from adenosine cofactors, such as AMPylation.
Figure 3. Volcano plot for the cofactor effect coefficients in the linear model, where positive values on the 
x-axis indicate preference for 2YnAd and negative values indicate preference for 6YnAd. The significance of 
the cofactor effect coefficients is computed using a moderated t-test based on the hierarchical Bayesian model 
as implemented in LIMMA, and adjusted p values (−log10 scale) are plotted on the y-axis with significantly 
enriched proteins coloured in red. Proteins reported to be ADP-ribosylated in other studies from ADPriboDB22 
are highlighted in bold.
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In summary, we have presented a quantitative chemical proteomics approach that combines metabolic label-
ling using clickable adenosine analogues with TMT isobaric MS to measure ADP-ribosylation in live cells with-
out experimental manipulation of PARG activity. We demonstrated that our method robustly profiled several 
thousands of intracellular protein targets, and yielded the largest quantitative proteomics data set measuring the 
ADP-ribosylome reported to date. The method is enabled by a dual metabolic labelling strategy using clickable 
NAD+ precursors 6YnAd and 2YnAd, with the latter demonstrating superior protein coverage. Robust pull-down 
of the modified proteins is achieved using the selective NeutrAvidin-Biotin interaction and the pooling effect 
resulting from utilising TMT isobaric tagging to multiplex experimental conditions provides increased sensitivity. 
A head-to-head comparison between two clinical PARP inhibitors revealed a correlative response, which further 
highlights the sensitivity and robustness of this chemical proteomics platform for studying ADP-ribosylation in 
live cells. This approach has also been applied to profile global ADP-ribosylation in other immortalised cell lines 
(e.g. MCF-7 breast cancer and HEK-293T fluorescence labelling images are provided in Suppl. Fig. 7) as well 
as primary cell lines. We envision this enabling chemical proteomics technology will transform our ability to 
systematically characterise the intracellular functions of ADP-ribosylation in fundamental and disease biology, 
including cancer research, bacterial and viral infections and autoimmune diseases. In addition, the approach 
will be instrumental in determining differences in the targets of established PARP inhibitors and the effects of an 
emerging range of novel compounds designed to be selective for particular PARP enzymes31.
Methods
Cell culture. MDA-MB-231 cells (ATCC) were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco) supplemented with 10% foetal bovine serum (FBS) (Gibco) without antibiotics in a humidified incubator 
with 5% CO2 at 37 °C and passaged at every 2–3 days at 80–90% confluency.
Figure 4. Schematic illustrating the workflow involving parallel treatment of PARP inhibitors Olaparib and 
Rucaparib followed by dual metabolic labelling of 6YnAd and 2YnAd, click chemistry, affinity enrichment of the 
labelled proteins on NeutrAvidin-Agarose beads and TMT10plex-based quantification of global changes in the 
cellular ADP-ribosylome.
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Figure 5. (A) Venn diagram assessment of the overlap between the proteins identified to be ADP-ribosylated 
in this study and previously published data sets. (B) Scatter plot showing mean log2 responses in the level of 
ADP-ribosylation of endogenous proteins to 25 µM of the inhibitors Olaparib and Rucaparib after removing the 
effects associated with technical replicate bias. Proteins whose response to inhibitors is significant (see LIMMA 
processing and statistical testing) are highlighted in orange. Proteins reported to be ADP-ribosylated in other 
studies from ADPriboDB14 are highlighted in bold. Factors involved in mRNA splicing are highlighted with a 
cyan rectangle around their labels. (C) Quantitative changes in the reporter intensities (log2 scale) of mRNA 
splicing proteins pre-mRNA splicing factor 38B (PRPF38B) and serine/arginine repetitive matrix protein 2 
(SRRM2) as a function of concentration of the inhibitors Olaparib (red) and Rucaparib (blue).
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Metabolic labelling and preparation of cell extracts. In a 6-well plate, 4 × 105 cells were treated with 
1 ml of fresh media (with 10% FBS) containing 2 µl of appropriate concentration of 6YnAd or 2YnAd (stock 
solutions in dimethyl sulfoxide [DMSO]) or DMSO control. For labelling experiments in 10 cm plates, 5 ml of 
fresh media with 10% FBS and 10 µl of the clickable adenosine analogue stock solutions were used. The cells were 
incubated at 37 °C and 5% CO2 for 1 h. The cells were then washed with PBS three times and lysed using 4% SDS 
lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 4% SDS and 500 U Benzonase) and whole-cell lysates were 
collected using a cell scraper. Lysates were cleared at 16,000 g for 5 min and protein concentrations were estimated 
using Bio-Rad DCTM protein assay.
Click chemistry and in-gel fluorescence detection. The cell lysates at 1 mg/ml concentration were 
treated with freshly premixed click chemistry reaction cocktail (100 µM capture reagent, 1 mM CuSO4 solu-
tion, 1 mM tris[2-carboxyethyl] phosphine hydrochloride [TCEP], 100 µM [tris(1-benzyl-1H-1,2,3-trazol-4-yl)
methyl]amine [TBTA]) for 3 h at room temperature. The following stock solutions of the click chemistry reagents 
were used. Capture reagent (Azido-TAMRA-Biotin or Azide-PEG3-Biotin (Jena Bioscience)): 10 mM in DMSO; 
CuSO4: 50 mM in MilliQ water; TCEP: 50 mM in MilliQ water; TBTA: 10 mM in DMSO. Proteins were precipi-
tated by adding ice-cold methanol (4 volumes), chloroform (1.5 volumes) and water (3 volumes) and the precip-
itates were collected by centrifugation at 16,000 g for 5 min. The protein precipitates were then washed twice with 
ice-cold methanol (10 volumes) and the supernatants were discarded. The protein pellets were air dried for 20 min 
and suspended in resuspension buffer (4% SDS, 50 mM HEPES pH 7.4, 150 mM NaCl) to 3 mg/ml concentration. 
Equal volumes of 2X SDS loading buffer (Bio-Rad) containing 10% β-mercaptoethanol were added and the sam-
ples were boiled at 95 °C for 10 min and allowed to cool to room temperature. 30 µg of protein was loaded per gel 
lane (12% SDS Tris-HCl gels) and resolved by SDS-PAGE. The gels were scanned for fluorescence labelling using 
a GE typhoon 5400 gel scanner.
Affinity enrichment on NeutrAvidin-Agarose. The dried protein pellets obtained after click chemis-
try and protein precipitation were suspended in resuspension buffer (4% SDS, 50 mM HEPES pH 7.4, 150 mM 
NaCl) to 10 mg/ml concentration. In a typical experiment, 500 µg of whole-cell lysate after click chemistry and 
protein precipitation was resuspended in 50 µl of the resuspension buffer. The samples were subsequently diluted 
20 fold with HEPES buffer (50 mM HEPES pH 7.5, 150 mM NaCl) so that the final SDS amount is 0.2%. 50 µl of 
NeutrAvidin-Agarose beads (Thermo scientific) were washed three times with 0.2% SDS buffer (0.2% SDS 50 mM 
HEPES pH 7.5, 150 mM NaCl) and added to the samples. The mixtures were rotated on an end-over-end rotating 
shaker for 1.5 h at room temperature. The beads were then washed 4 times with 1% SDS buffer (1% SDS, 50 mM 
HEPES pH 7.5, 150 mM NaCl), 4 times with 5 M urea buffer (5 M urea in 50 mM HEPES pH 7.5, 150 mM NaCl) 
and 4 times with 50 mM freshly prepared ammonium bicarbonate buffer. Each washing was performed with 
20 volumes of the washing solutions and centrifugation of the beads between washing steps were carried out at 
2,000 g for 1 min. For Western blot analysis, the beads, after one round of washing with 1% SDS buffer, were boiled 
in 4% SDS loading buffer and the proteins were collected by centrifugation. For LC-MS/MS analysis, on-bead 
reduction, alkylation and tryptic digestion were performed.
Western blotting. Proteins resolved by SDS-PAGE on 12% Tris-HCl gels were electrotransferred onto a 
nitrocellulose membrane. Western blotting for ADP-ribosylation was performed using anti-pan-ADP-ribose 
antibody (MABE1016, lot # 3074935, EMD Millipore) as described earlier with minor modifications11. Briefly, the 
nitrocellulose membrane after electrotransfer was blocked with freshly prepared 5% BSA in TBS-T for 1 hour at 
room temperature with constant shaking. The membrane was then incubated with the primary antibody (1:1000 
dilution) in 5% BSA in TBS-T for 1 hour at room temperature with constant shaking. The membrane was then 
washed 4 times for 5 minutes with TBS-T and incubated with Goat-anti-rabbit IgG-HRP secondary antibody 
(1:5000 dilution) in 5% BSA in TBS-T for 1 hour at room temperature with constant shaking, washed again 4 
times for 15 minutes with TBS-T and visualised with PierceTM ECL Plus Western blotting substrate (Thermo 
Scientific, Prod # 32132, Lot # SD244941).
On-bead reduction, alkylation, tryptic digestion and desalting. The beads after affinity enrichment 
were resuspended in 100 µl of 50 mM ammonium bicarbonate buffer and treated with 3 mM dithiothreitol (DTT) 
(100 mM stock solution in water) solution for 30 min at room temperature. The beads were washed once with 
50 mM ammonium bicarbonate buffer and resuspended in 100 µl of 50 mM ammonium bicarbonate buffer and 
treated with 10 mM iodoacetamide (IAA) (500 mM stock solution in water) in dark for 30 min at room tempera-
ture. The beads were again washed with 50 mM ammonium bicarbonate buffer and resuspended in 100 µl of fresh 
50 mM ammonium bicarbonate buffer and treated with 2 µg of sequencing grade modified trypsin (Promega; 
Product code V5113) at 37 °C overnight. The samples were acidified to pH 3 using formic acid and allowed to 
stand for 5 min, centrifuged and collected the supernatant. The beads were washed with 0.1% formic acid solu-
tion in water, centrifuged and the supernatant were mixed with the previous supernatant. The collected tryptic 
peptides were desalted on C18 Empore disks on micropipette tip format and the desalted peptide mixture were 
dried on a speedvac.
TMTsixplex labeling. MDA-MB-231 cells were fed with three different concentrations (1, 0.5 and 0.25 mM) 
of 6YnAd and 2YnAd in parallel. After 1 h of incubation, whole-cell lysates were prepared and proteins were 
quantified. 500 µg of proteins from each condition were subjected to click chemistry using the capture rea-
gent Azido-TAMRA-Biotin. Proteins were precipitated, re-solubilised and subjected to affinity enrichment on 
NeutrAvidin-Agarose beads. After extensive washings, the beads were subjected to DTT treatment, IAA treat-
ment and overnight trypsinisation. The peptide digests were collected, desalted, dried and re-dissolved in 100 µl 
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of 100 mM triethylammonium bicarbonate (TEAB) buffer (pH 8.5). Each sample was subjected to TMT labelling 
with a unique TMTsixplex reagent for 1 h at room temperature. After quenching the TMT reactions with hydrox-
ylamine (10 µL of 5% hydroxylamine per reaction for 15 min at room temperature) treatment, the six samples 
were mixed together, concentrated to complete dryness and re-dissolved in 0.1% formic acid. The sample was 
desalted on C18 Empore disks on micropipette tip format and the desalted sample was dried on a speedvac.
Mass-spectrometry analysis of TMT labelled samples. Peptides were reconstituted in 0.1% trifluoro-
acetic acid and chromatographically resolved using an Ultimate 3000 RSLCnano (Dionex) UHPLC. Peptides were 
first loaded onto an Acclaim PepMap 100 C18, 3 µm particle size, 100 Å pore size, 20 mm × 75 µm ID (Thermo 
Scientific) trap column heated to 40 °C, using a loading buffer (2% acetonitrile (MeCN) and 0.05% trifluoro-
acetic acid in 97.05% H2O) with a flow rate of 7 µL/minute. Chromatographic separation was achieved using 
an EASY-Spray column, PepMap C18, 2 µm particles, 100 Å pore size, 500 mm × 75 µm ID (Thermo Scientific) 
heated to 40 °C. The gradient utilised a flow of 0.3 µL/minute, starting at 98% mobile A (0.1% formic acid, 5% 
DMSO in H2O) and 2% mobile B (0.1% formic acid, 75% acetonitrile, 5% DMSO and 19.9% H2O). After 5.5 min-
utes mobile B was increased to 8% over 0.5 minutes, to 30% over 27 minutes, further increased to 40% in 10 min-
utes, and finally up to 95% in 2 minutes and held for 4 minutes. Mobile B was reduced back to 5% over 1 minute 
for the rest of the acquisition.
Data was acquired in real time over 60 minutes using an Orbitrap Fusion Lumos Tribrid mass spectrometer 
(Thermo Scientific). Eluents were ionised using 2.1 kV spray voltage and a capillary temperature of 275 °C. For all 
samples MS1 spectra were measured with a resolution of 120,000 at 200 m/z and a mass range of 375 to 1500 m/z, 
with a 50 ms maximum injection time, and 4e5 AGC target.
High-resolution HCD MS2 spectra were generated in positive mode for precursor masses using a normalised 
collision energy of 38%, within a 0.7 m/z isolation window, using quadrupole isolation, in top speed mode over a 
3 second cycle time, at 50,000 resolution in profile mode, 100 ms maximum injection time and 5e4 AGC target, 
with an instrument determined scan range beginning at 100 m/z.
To ensure quality peptide fragmentation, a number of filters were utilised, including; peptide mono isotopic 
precursor selection, minimum intensity exclusion of 5e4, and charge state inclusion of 2–5 + ions. To prevent 
repeat sampling a dynamic exclusion with exclusion count 1, exclusion duration of 30 seconds, +/−10 ppm tol-
erance window, with isotope exclusion and single charge state selection were used.
Mass-spectrometry data processing. All raw files were analysed using MaxQuant software (version 
1.5.3.30) queried against the Uniprot complete human database (October 2017). The following search parameters 
were used: Reporter ion MS2 with multiplicity 6plex TMT for the TMTsixplex experiments and 10plex TMT for 
the TMT10plex experiments, trypsin digestion with maximum 2 missed cleavages, oxidation of methionine and 
acetylation of protein N-termini as variable modifications, carbamidomethylation of cysteine as a fixed modifi-
cation, minimum peptide length of 6, protein FDR 0.01. Appropriate correction factors for the individual TMT 
channels for both peptide N-terminal labelling and lysine side-chain labelling as per the TMT kits used (Thermo 
Scientific) were configured into the integrated Andromeda search prior to the MaxQuant search.
PARP inhibitor treatment, dual metabolic incorporation and TMT10plex labeling. MDA-MB-231 
cells grown to 80–90% confluency in 10 cm plates were treated with 25, 5, 1, 0.2 and 0 (DMSO control) µM concen-
trations of the PARP inhibitors Olaparib (10 mM stock solution in DMSO) and Rucaparib (10 mM stock solution in 
DMSO) in parallel. All treatments were performed in 10 ml DMEM with 10% FBS and the cells were placed in an 
incubator with 5% CO2 and 37 °C for 1 h. After 1 h, the media were removed and the cells were supplemented with fresh 
complete media (5 ml) containing 0.25 mM concentrations of both 6YnAd (500 mM stock solution in DMSO) and 
2YnAd (500 mM stock solution in DMSO) continued incubation for one more hour. The cells were washed with PBS 
three times and whole-cell lysates were prepared and proteins were quantified. 500 µg protein per each condition were 
subjected to click reactions using Azide-PEG3-Biotin capture reagent. Proteins were precipitated using the methanol/
chloroform/water system and air-dried precipitates were resuspended in the pull-down buffer (50 mM HEPES, pH 7.4, 
0.2% SDS, 150 mM NaCl) and subjected to affinity enrichment on NeutrAvidin-Agarose beads. After extensive wash-
ings, the beads were subjected to DTT treatment, IAA treatment and overnight trypsinisation. The peptide digests from 
the 10 conditions were collected, desalted, dried and re-dissolved in 100 µl of 100 mM triethylammonium bicarbonate 
(TEAB) buffer (pH 8.5). Each sample was subjected to TMT labelling with a unique TMT10plex reagent for 1 h at room 
temperature. After quenching the TMT reactions with hydroxylamine treatment, the 10 samples were mixed together, 
concentrated to complete dryness and re-dissolved in 0.1% formic acid solution in water. The sample was desalted 
on C18 Empore disks on micropipette tip format and the desalted sample was dried on a speedvac. The sample was 
dissolved in 300 µl of 0.1% TFA solution in water and subjected to fractionation using High pH Reverse-Phase Peptide 
Fractionation Kit (Thermo scientific) to 8 fractions and dried on a speedvac.
Pre-processing of MaxQuant output for data analysis. Columns corresponding to the corrected 
reporter intensity were extracted from the proteinGroups.txt files in MaxQuant output. Potential contaminants, 
proteins only identified by site, reverse proteins and proteins containing less than two peptides were discarded. 
Out of the remaining proteins, only proteins that have non-zero intensities across all reporters and replicates were 
kept (1604 proteins in 2YnAd-6YnAd dataset, 2334 in the inhibitor dataset). Intensities of the remaining proteins 
were normalised using TMM method32 and converted to log2-per-million values. The resulting data was then 
compared with previously reported annotations of ADP-ribosylated proteins available in ADPriboDB (v1.0)13, 
which was augmented to include annotations reported since 2015 (v2.0; unpublished), after prefiltering the data-
base to contain only annotations derived from human datasets.
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LIMMA linear model design. Both cofactor preference and inhibitor treatment datasets were analysed 
using LIMMA method. The linear methods for each of these datasets were designed separately and described 
below.
2YnAD/6YnAD. The normalised intensities are assumed to be modelled by the following effects in a format 
described below:
+
+ + .
~log2(normalised intensity) [Cofactor effect, Sum encoding]
[log(concentration) effect]
[Replicate effect] Intercept
We used the following encoding for the effects.
 1. Cofactor effect (i.e. the main measured effect). Encoded by +1 in reporters corresponding to 2YnAd and 
−1 in reporters corresponding to 6YnAd (e.g. sum-to-one encoding). Positive coefficients to this factor 
therefore indicate 2YnAd preference, and negative values indicate 6YnAd preference.
 2. log(concentration) effect: encoded as log values of the concentrations in mM. Effect is assumed to be the 
same for both cofactors. Higher values indicate stronger response.
 3. Replicate: 1-of-K encoding (minus one redundant term absorbed in intercept). This term accounts for 
technical-replicate associated bias in protein intensities.
The complete design matrix is available as Supplementary Table 1.
PARP Inhibitor dataset. For this dataset we have applied the linear modelling only on the data points corre-
sponding to 25 µM of inhibitor and 0 µM (reporters 0, 4, 5 and 9), not taking into account the data for intermedi-
ate concentrations to avoid overfitting. The following linear model was assumed.
+
+ + .
~Log(intensity) [Inhibitor preference effect] [Inhibition effect]
[Replicate bias] [Intercept]
The three factors have been encoded as follows:
 1. Inhibitor preference effect. One of the two major effects in this experiment. This factor is designed to cap-
ture the effect of a particular inhibitor on the intensity of the protein. We encoded this using the following 
map: −1 = Olaparib, +1 = Rucaparib and 0 = No inhibitor (i.e. concentration = 0 µM). In this way, positive 
values correspond to protein having to higher intensity upon Rucaparib treatment and negative values 
corresponding to higher intensity upon Olaparib treatment.
 2. Inhibition effect. This term corresponds to the second major effect in the experiment, which captures the 
general effect of inhibition to the protein that does not depend on the inhibitor. It was encoded as 1 (in 
cases where inhibitor is present) and 0 otherwise. This way values below than zero correspond to decrease 
in intensity upon inhibition.
 3. Replicate bias: This term accounts for technical-replicate associated bias in protein intensities. This was 
encoded with one-in-K encoding with one redundant term absorbed to intercept.
The complete design matrix is available in Supplementary Table 2.
LIMMA processing and statistical testing. We have used a similar procedure to the one described by 
Kammers et al.33. The linear models were encoded as described above. LIMMA analysis was run with the trend 
parameter set to TRUE (commonly referred to as LIMMA-trend method). After the model has been fit, we have 
performed statistical testing on the effect coefficients in the model using the equations provided by Kammers et 
al. Specifically, we have tested the null hypothesis that cofactor effect coefficient is zero in 2YnAd/6YnAd dataset, 
and the null hypotheses that inhibitor preference effect and inhibition effect coefficients are not zero (separately) 
in inhibitor treatment dataset. The p values were adjusted with Benjamini-Hochberg method. Any adjusted p 
values below 0.01 were deemed significant and annotated in the plots and output. In order to generate debiased 
plots, we have subtracted the values for bias coefficients (e.g. replicate bias and intercept) from the normalised 
log2 intensities.
Pathway enrichment analysis. Biological pathway enrichment analysis was performed against Reactome 
database34 using the R packages ReactomePA35 and clusterProfiler36 using the default settings, showing the most 
descriptive categories with the “by = rowPercentage” parameter set.
Data Availability
The tandem mass spectrometry datasets generated during the current study are available via the PRIDE database 
(project accession: PXD011631). All of the data analysed during this study are included in this published article 
(and its Supplementary Information files).
1 1Scientific RepoRts |          (2019) 9:6655  | https://doi.org/10.1038/s41598-019-43154-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
References
 1. Hottiger, M. O. Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics. Annu. Rev. 
Biochem. 84, 227–263 (2015).
 2. Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152–1158 (2017).
 3. Jungmichel, S. et al. Proteome-wide identification of poly(ADP-Ribosyl)ation targets in different genotoxic stress responses. Mol. 
Cell 52, 272–285 (2013).
 4. Martello, R. et al. Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue. Nat. Commun. 
7, 12917 (2016).
 5. Zhang, Y., Wang, J., Ding, M. & Yu, Y. Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. Nat. Methods 
10, 981–984 (2013).
 6. Gagne, J. P. et al. Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein 
complexes. Nucleic Acids Res. 36, 6959–6976 (2008).
 7. Daniels, C. M., Ong, S. E. & Leung, A. K. Phosphoproteomic approach to characterize protein mono- and poly(ADP-ribosyl)ation 
sites from cells. J. Proteome Res. 13, 3510–3522 (2014).
 8. Min, W., Cortes, U., Herceg, Z., Tong, W. M. & Wang, Z. Q. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase 
(PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis 31, 2058–2065 (2010).
 9. Grammel, M., Hang, H. & Conrad, N. K. Chemical reporters for monitoring RNA synthesis and poly(A) tail dynamics. 
ChemBioChem 13, 1112–1115 (2012).
 10. Westcott, N. P., Fernandez, J. P., Molina, H. & Hang, H. C. Chemical proteomics reveals ADP-ribosylation of small GTPases during 
oxidative stress. Nat. Chem. Biol. 13, 302–308 (2017).
 11. Gibson, B. A. et al. Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation. Science 353, 
45–50 (2016).
 12. Dayon, L. et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal. Chem. 
80, 2921–2931 (2008).
 13. Vivelo, C. A., Wat, R., Agrawal, C., Tee, H. Y. & Leung, A. K. ADPriboDB: The database of ADP-ribosylated proteins. Nucleic Acids 
Res. 45, D204–D209 (2017).
 14. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 
43, e47 (2015).
 15. Knezevic, C. E. et al. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell 
Chem. Biol. 23, 1490–1503 (2016).
 16. Jiang, H., Kim, J. H., Frizzell, K. M., Kraus, W. L. & Lin, H. Clickable NAD analogues for labeling substrate proteins of poly(ADP-
ribose) polymerases. J. Am. Chem. Soc. 132, 9363–9372 (2010).
 17. Wang, Y., Rösner, D., Grzywa, M. & Marx, A. Chain-terminating and clickable NAD(+) analogues for labeling the target proteins of 
ADP-ribosyltransferases. Angew. Chem. Int. Ed. 53, 8159–8162 (2014).
 18. Carter-O’Connell, I., Jin, H., Morgan, R. K., David, L. L. & Cohen, M. S. Engineering the substrate specificity of ADP-
ribosyltransferases for identifying direct protein targets. J. Am. Chem. Soc. 136, 5201–5204 (2014).
 19. Wallrodt, S., Buntz, A., Wang, Y., Zumbusch, A. & Marx, A. Bioorthogonally Functionalized NAD(+) Analogues for In-Cell 
Visualization of Poly(ADP-Ribose) Formation. Angew. Chem. Int. Ed. 55, 7660–7664 (2016).
 20. Buntz, A. et al. Real-Time Cellular Imaging of Protein Poly(ADP-ribos)ylation. Angew. Chem. Int. Ed. 55, 11256–11260 (2016).
 21. Curanovic, D. et al. Global profiling of stimulus-induced polyadenylation in cells using a poly(A) trap. Nat. Chem. Biol. 9, 671–673 
(2013).
 22. Cho-Park, P. F. & Steller, H. Proteasome regulation by ADP-ribosylation. Cell 153, 614–627 (2013).
 23. Kakarougkas, A. et al. Co-operation of BRCA1 and POH1 relieves the barriers posed by 53BP1 and RAP80 to resection. Nucleic 
Acids Res. 41, 10298–10311 (2013).
 24. Haikarainen, T., Krauss, S. & Lehtio, L. Tankyrases: structure, function and therapeutic implications in cancer. Curr. Pharm. Des. 20, 
6472–6488 (2014).
 25. Matveeva, E. et al. Involvement of PARP1 in the regulation of alternative splicing. Cell Discov 2, 15046 (2016).
 26. Jubin, T. et al. Poly ADP-ribose polymerase-1: Beyond transcription and towards differentiation. Semin. Cell Dev. Biol. 63, 167–179 
(2017).
 27. Ji, Y. & Tulin, A. V. Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins. Int. J. Mol. Sci. 14, 
16168–16183 (2013).
 28. Ji, Y. & Tulin, A. V. Poly(ADP-ribosyl)ation of heterogeneous nuclear ribonucleoproteins modulates splicing. Nucleic Acids Res. 37, 
3501–3513 (2009).
 29. Melikishvili, M., Chariker, J. H., Rouchka, E. C. & Fondufe-Mittendorf, Y. N. Transcriptome-wide identification of the RNA-binding 
landscape of the chromatin-associated protein PARP1 reveals functions in RNA biogenesis. Cell Discov. 3, 17043 (2017).
 30. Zimmermann, M. et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 559, 
285–289 (2018).
 31. Thorsell, A.-G. et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase 
Inhibitors. J Med Chem 60, 1262–1271 (2017).
 32. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 
11, R25 (2010).
 33. Kammers, K., Cole, R. N., Tiengwe, C. & Ruczinski, I. Detecting Significant Changes in Protein Abundance. EuPA Open Proteom. 7, 
11–19 (2015).
 34. Fabregat, A. et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res. 46, D649–D655 (2018).
 35. Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol. BioSyst. 12, 
477–479 (2016).
 36. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 
16, 284–287 (2012).
Acknowledgements
This work was supported by GlaxoSmithKline through the Imperial College London Engineering Medicines 
Laboratory Project (K.A.K, D.O.H and P.A.D) and the UK Biotechnology and Biological Sciences Research 
Council Doctoral Training Partnership award (S.L). A.P.S. and A.B. are supported by the Francis Crick Institute, 
which receives its core funding from Cancer Research UK (FC001999), the UK Medical Research Council 
(FC001999) and the Wellcome Trust (FC001999).
1 2Scientific RepoRts |          (2019) 9:6655  | https://doi.org/10.1038/s41598-019-43154-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Author Contributions
K.K. and P.A.D. conceived of the study; K.K. performed experiments; S.L. and P.A.D. performed statistical 
analysis of data; K.K., S.L., A.J.B., A.P.S., D.O.H., V.A., A.K.L.L. and P.A.D. contributed to experimental design, 
data analysis and data interpretation. K.K. and P.A.D. wrote the manuscript with input from all authors.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43154-1.
Competing Interests: K.K., S.L. and P.A.D. have a patent application pending for the utilisation of the dual 
metabolic labelling using 2YnAd and 6YnAd for identification of intracellular ADP-ribosylation (Application 
number: 1810697.1). A.J.B., A.P.S., D.O.H., V.A. and A.K.L.L. declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
